Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDGFRB | P09619 | 6/20 | 0.74 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.74 |
| ▸ | FLT3 | P36888 | 4/20 | 0.64 |
| ▸ | SMO | Q99835 | 1/20 | 0.59 |
| ▸ | TUBB4A | P04350 | 5/20 | 0.57 |
| ▸ | TUBB | P07437 | 5/20 | 0.57 |
| ▸ | TUBA3C | P0DPH7 | 5/20 | 0.57 |
| ▸ | TUBA1B | P68363 | 5/20 | 0.57 |
| ▸ | TUBA4A | P68366 | 5/20 | 0.57 |
| ▸ | TUBB4B | P68371 | 5/20 | 0.57 |
| ▸ | TUBB3 | Q13509 | 5/20 | 0.57 |
| ▸ | TUBB2A | Q13885 | 5/20 | 0.57 |
| ▸ | TUBB8 | Q3ZCM7 | 5/20 | 0.57 |
| ▸ | TUBA3E | Q6PEY2 | 5/20 | 0.57 |
| ▸ | TUBA1A | Q71U36 | 5/20 | 0.57 |
| ▸ | TUBA1C | Q9BQE3 | 5/20 | 0.57 |
| ▸ | TUBB6 | Q9BUF5 | 5/20 | 0.57 |
| ▸ | TUBB2B | Q9BVA1 | 5/20 | 0.57 |
| ▸ | TUBB1 | Q9H4B7 | 5/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL424534 | 0.86 | PDGFRB (0.59) | PDGFRBPDGFRAFLT3SMOTUBB4A | |
| SCHEMBL426498 | 0.84 | PDGFRB (0.72) | PDGFRBPDGFRAFLT3MEN1CYP1A2 | |
| SCHEMBL7065750 | 0.84 | FLT3 (0.64) | PDGFRBPDGFRAFLT3TUBB4ATUBB | |
| SCHEMBL426735 | 0.84 | FLT3 (0.60) | PDGFRBPDGFRAFLT3TUBB4ATUBB | |
| SCHEMBL430120 | 0.84 | FLT3 (0.64) | PDGFRBPDGFRAFLT3TUBB4ATUBB | |
| SCHEMBL12677623 | 0.83 | PDGFRB (0.58) | PDGFRBPDGFRAFLT3SMOTUBB4A | |
| SCHEMBL425103 | 0.83 | FLT3 (0.60) | PDGFRBPDGFRAFLT3TUBB4ATUBB | |
| SCHEMBL429717 | 0.83 | PDGFRB (0.60) | PDGFRBPDGFRAFLT3TUBB4ATUBB | |
| SCHEMBL426733 | 0.83 | MEN1 (0.65) | PDGFRBPDGFRAFLT3TUBB4ATUBB | |
| SCHEMBL31705824 | 0.83 | FLT3 (0.64) | PDGFRBPDGFRAFLT3TUBB4ATUBB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104586842-B | Anti-cancer activity indole derivative, synthesis method and uses thereof | 温州大学 | 2017-04-12 | — | — | CN | claimed |
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2012-01-26 | — | — | US | disclosed |
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | BAXTER ONCOLOGY GMBH | 2003-08-21 | — | — | US | disclosed |
| US-20020091124-A1 | 2-acyl indole derivatives and their use as antitumor agents | BECKERS THOMAS (DE) | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022121-A1 | INDOLES, DERIVATIVES AND ANALOGS THEREOF AND USES THEREFOR | TUBB, TUBB3, TUBB1 | PDGFRB 2578/4885PDGFRA 2983/4885FLT3 3889/4885 |
| US-20030158216-A1 | 2-acyl indole derivatives and their use as antitumor agents | IDO1, IDO2, INMT | PDGFRB 3807/4885PDGFRA 3147/4885FLT3 1953/4885 |
| US-20020091124-A1 | 2-acyl indole derivatives and their use as antitumor agents | IDO1, IDO2, INMT | PDGFRB 3807/4885PDGFRA 3147/4885FLT3 1953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.